Skip to main content

Table 4 Association between albuminuria, hypertension, dyslipidemia and GFL-slope categories

From: Renal function deterioration in adult patients with type-2 diabetes

 

Univariate

frequency (95%CI)

Model 1

frequency (95%CI)

Model 2

frequency (95%CI)

p-value Model 2

Microalbuminuria (%)

 eGFR-increasea > 12

42.3 (41.3–43.4)

42.9 (41.7–44.1)

42.8 (41.6–44.0)

< 0.001

 eGFR-increasea 0 up to + 12

40.4 (39.2–41.6)

40.3 (39.1–41.5)

40.3 (39.1–41.5)

 

 eGFR-slopea 0 down to −12

41.8 (40.5–43.2)

41.4 (40.1–42.8)

41.3 (40.0–42.7)

 

 eGFR-slopea -12 or smaller

50.9 (49.7–52.0)

49.4 (48.2–50.7)

49.1 (47.9–50.4)

 

Hypertension (%)

 eGFR-increasea > 12

83.6 (82.9–84.4)

88.4 (87.7–89.1)

n.a.

0.002b

 eGFR-increasea 0 up to + 12

88.0 (87.3–88.8)

89.0 (88.2–89.7)

n.a.

 

 eGFR-slopea 0 down to −12

89.9 (89.2–90.7)

89.9 (89.0–90.6)

n.a.

 

 eGFR-slopea < −12 or smaller

91.8 (91.3–92.4)

90.4 (89.7–91.1)

n.a.

 

Dyslipidemia (%)

 eGFR-increasea > 12

68.7 (67.7–69.6)

70.7 (69.6–71.7)

72.4 (71.3–73.4)

< 0.001

 eGFR-increasea 0 up to + 12

68.2 (67.1–69.2)

68.2 (67.1–69.3)

69.9 (68.8–71.0)

 

 eGFR-slopea 0 down to −12

69.2 (68.0–70.4)

69.0 (67.8–70.2)

70.4 (69.2–71.6)

 

 eGFR-slopea < −12 or smaller

59.1 (58.1–60.2)

58.9 (57.7–60.0)

58.7 (57.5–60.0)

 
  1. Legend:aWithin a time span of 3 years; bp-value Model 1; Model 1 adjusted for age, sex, duration and BMI; Model 2 adjusted for model 1 variables plus ACE-inhibitor use and/or ARB use